Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Daniel Haldar"'
Autor:
Melissa R. Lyman, Jacob T. Mitchell, Luciane T. Kagohara, Benjamin Barrett, Amanda Huff, Sarah Shin, Gabriella Longway, Anuj Gupta, Lalitya Andaloori, Todd D. Armstrong, Daniel Haldar, Robert Anders, Elizabeth Thompson, Nilo Azad, Won Jin Ho, Elizabeth Jaffee, Elana J. Fertig, Neeha Zaidi
Publikováno v:
Cancer Research. 83:2873-2873
Pancreatic ductal adenocarcinoma (PDAC) is most often diagnosed at an advanced stage. Newly diagnosed patients therefore have a dismal five-year survival rate of 11%. However, PDAC progresses from pre-invasive pancreatic intraepithelial neoplasia (Pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8d585388287ad254964b759cc0e98c28
https://doi.org/10.1158/1538-7445.am2023-2873
https://doi.org/10.1158/1538-7445.am2023-2873
Autor:
Saurav Daniel Haldar, Thatcher Ross Heumann, Maureen Berg, Anna Ferguson, Su Jin Lim, Hao Wang, Julie Nauroth, Dan Laheru, Elizabeth M. Jaffee, Nilofer Saba Azad, Neeha Zaidi
Publikováno v:
Journal of Clinical Oncology. 41:TPS814-TPS814
TPS814 Background: Novel strategies are needed to improve immune responses in “cold” tumors such as pancreatic ductal adenocarcinoma (PDAC) and mismatch repair-proficient colorectal cancer (MMRp CRC). As a frequent oncogenic driver, mutant KRAS (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fdf3bb2b470253e92e14da2ac3ad10b1
https://doi.org/10.1200/jco.2023.41.4_suppl.tps814
https://doi.org/10.1200/jco.2023.41.4_suppl.tps814
Autor:
Saurav Daniel Haldar, Carol Judkins, Anna Ferguson, Elizabeth Abou Diwan, Su Jin Lim, Hao Wang, Julie Nauroth, Michael Goggins, Dan Laheru, Elizabeth M. Jaffee, Nilofer Saba Azad, Neeha Zaidi
Publikováno v:
Journal of Clinical Oncology. 41:TPS758-TPS758
TPS758 Background: KRAS mutations are identified in the majority of premalignant lesions that precede pancreatic ductal adenocarcinoma (PDAC). Arising during tumorigenesis, mutant KRAS (mKRAS) neoantigens are less susceptible to central tolerance mec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1df1511b4fe28bd29246df3fd96cf7ab
https://doi.org/10.1200/jco.2023.41.4_suppl.tps758
https://doi.org/10.1200/jco.2023.41.4_suppl.tps758
Autor:
Neeha Zaidi, Amanda Huff, Emily Marcisak-Davis, Daniel Haldar, Thatcher Heumann, Max Konig, Brian Mog, Janelle Montagne, Gabriella Longway, Lalitya Andaloori, Melissa Lyman, Ludmila Danilova, Julie Nauroth, Luciane Kagohara, Elana Fertig, Nilo Azad, Elizabeth Jaffee
Publikováno v:
Cancer Research. 82:IA013-IA013
The evolution of pancreatic ductal adenocarcinoma (PDAC) from tumor initiation to metastases requires years to decades, providing a window of opportunity for the prevention of premalignant progression. One of the first genetic mutations to occur earl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::209f0c9253191e1599962ef1e131f6bb
https://doi.org/10.1158/1538-7445.panca22-ia013
https://doi.org/10.1158/1538-7445.panca22-ia013
Autor:
Melissa C. Holt, Zahra Assar, Reza Beheshti Zavareh, Lin Lin, Justin Anglin, Oksana Mashadova, Daniel Haldar, Edouard Mullarky, Daniel M. Kremer, Lewis C. Cantley, Alec C. Kimmelman, Adam J. Stein, Luke L. Lairson, Costas A. Lyssiotis
Publikováno v:
Biochemistry. 57:6604-6614
Pancreatic cancer cells are characterized by deregulated metabolic programs that facilitate growth and resistance to oxidative stress. Among these programs, pancreatic cancers preferentially utilize a metabolic pathway through the enzyme aspartate am
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28f0132c70b3f3925ded93a2125cdd5f
https://doi.org/10.1021/acs.biochem.8b00914
https://doi.org/10.1021/acs.biochem.8b00914
Autor:
Daniel Haldar, Justin L. Anglin, Reza Beheshti Zavareh, Costas A. Lyssiotis, Alec C. Kimmelman, Philipp N. Sander, Luke L. Lairson, Lewis C. Cantley, Edouard Mullarky
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 28:2675-2678
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy that is extremely refractory to the therapeutic approaches that have been evaluated to date. Recently, it has been demonstrated that PDAC tumors are dependent upon a metabolic pathway inv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb1a04df638737d00f17551697fa493e
https://doi.org/10.1016/j.bmcl.2018.04.061
https://doi.org/10.1016/j.bmcl.2018.04.061